x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Few & Far Between: Conversations from the Front Lines of Drug Development

Welcome to Few & Far Between! Chris O"Brien, CEO of Biorasi, is your host for Conversations from the Front Lines of Drug Development - from clinical research and policymakers to biotech innovators and industry leaders.

science life sciences

All Episodes

01:01:16

Video Episode 63 - Bruce Leuchter, MD, President and...

Few & Far Between: Conversations from the Front Lines... ·

2025/10/28

What if the future of biotech is actually late-stage execution? Welcome to our first video episode of the Biorasi Few & Far Between podcast with your host, Chris O’Brien. Today, we welcome guest Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences. We’ll be covering a myriad of biotech topics, from “business athletes” to the role of the operating company in the drug development industry. We’ll also be premiering our lightning round - quick

en

00:44:15

Episode 62: Ken Suzuki, Chief Marketing Officer at...

Few & Far Between: Conversations from the Front Lines... ·

2025/10/22

When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology. Listen in as we access the marketer inside each of us, discuss how knowing people might be more important than business and finance, and follow the steps to maintain the fine balance between marketing and

en

00:44:15

Episode 62: Ken Suzuki, Chief Marketing Officer at...

Few & Far Between: Conversations from the Front Lines... ·

2025/10/22

When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology. Listen in as we access the marketer inside each of us, discuss how knowing people might be more important than business and finance, and follow the steps to maintain the fine balance between marketing and

en

00:45:18

Episode 61: Woody Bryan, President and CEO of Revolo...

Few & Far Between: Conversations from the Front Lines... ·

2025/10/01

Why is a feather-light touch important in fighting infections? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we press the reset button on the human immune system, explore upstream and downstream levers for treating autoimmune diseases, and how to stay competitive in the biotech industry. Let's start the podcast!

en

00:45:18

Episode 61: Woody Bryan, President and CEO of Revolo...

Few & Far Between: Conversations from the Front Lines... ·

2025/10/01

Why is a feather-light touch important in fighting infections? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we press the reset button on the human immune system, explore upstream and downstream levers for treating autoimmune diseases, and how to stay competitive in the biotech industry. Let's start the podcast!

en

00:42:11

Episode 60: Part Two: Yochi Slonim, Co-Founder and...

Few & Far Between: Conversations from the Front Lines... ·

2025/09/17

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Get ready for part two of this special two-part episode as we touch on smarter LLMs, evolved AI agents, and connecting data to real-world biology. Okay, let's start the podcast!

en

00:42:11

Episode 60: Part Two: Yochi Slonim, Co-Founder and...

Few & Far Between: Conversations from the Front Lines... ·

2025/09/17

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Get ready for part two of this special two-part episode as we touch on smarter LLMs, evolved AI agents, and connecting data to real-world biology. Okay, let's start the podcast!

en

00:43:41

Episode 59, Part One: Yochi Slonim, Co-Founder and...

Few & Far Between: Conversations from the Front Lines... ·

2025/09/03

What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology. Okay, let's start the podcast!

en

00:43:41

Episode 59, Part One: Yochi Slonim, Co-Founder and...

Few & Far Between: Conversations from the Front Lines... ·

2025/09/03

What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology. Okay, let's start the podcast!

en

00:44:43

Episode 58: Jerry McLaughlin, CEO and Board Member at...

Few & Far Between: Conversations from the Front Lines... ·

2025/08/14

How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial. Tune in today!

en

00:44:43

Episode 58: Jerry McLaughlin, CEO and Board Member at...

Few & Far Between: Conversations from the Front Lines... ·

2025/08/14

How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial. Tune in today!

en

00:44:53

Episode 57: Jim Brown, DVM, President and CEO of...

Few & Far Between: Conversations from the Front Lines... ·

2025/07/22

Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research. Tune in today!

en

00:44:53

Episode 57: Jim Brown, DVM, President and CEO of...

Few & Far Between: Conversations from the Front Lines... ·

2025/07/22

Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research. Tune in today!

en

00:39:28

Episode 56, Part Two: Michael Tolentino, MD,...

Few & Far Between: Conversations from the Front Lines... ·

2025/07/15

How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs. Okay, let's start the podcast!

en

00:39:28

Episode 56, Part Two: Michael Tolentino, MD,...

Few & Far Between: Conversations from the Front Lines... ·

2025/07/15

How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs. Okay, let's start the podcast!

en

00:38:46

Episode 55: Julio G. Martinez-Clark, CEO and...

Few & Far Between: Conversations from the Front Lines... ·

2025/07/09

How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region. In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval.

en

00:38:46

Episode 55: Julio G. Martinez-Clark, CEO and...

Few & Far Between: Conversations from the Front Lines... ·

2025/07/09

How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region. In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval.

en

00:45:11

Episode 54, Part One: Michael Tolentino, MD,...

Few & Far Between: Conversations from the Front Lines... ·

2025/05/28

The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of

en

00:45:11

Episode 54, Part One: Michael Tolentino, MD,...

Few & Far Between: Conversations from the Front Lines... ·

2025/05/28

The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of

en

00:50:46

Episode 53: Frank David, Founder and Managing...

Few & Far Between: Conversations from the Front Lines... ·

2025/04/29

How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation. Listen in to the latest episode of the Biorasi Few & Far Between podcast today!

en

113 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter